



ASX RELEASE

VOLPARA FULL YEAR RESULTS AND INVESTOR CONFERENCE CALL NOTIFICATION

Wellington, NZ, 25th May 2020: Volpara Health Technologies Limited (**Volpara**; ASX: VHT), a medical technology company whose cancer screening software platform assists in the delivery of personalized patient care, advises it will release its Full Year Results for the period ending 31st March 2020, on Friday 29th May 2020.

Investors are invited to join a conference call hosted by CEO, Dr Ralph Highnam and CFO, Craig Hadfield on Friday 29th May 2020 at 9:00am Australian Eastern Standard Time (AEST).

To pre-register, please follow this link:

<https://s1.c-conf.com/DiamondPass/10007311-invite.html>

You will receive a calendar notification with dial-in details and a PIN for fast-track access to the call.

ENDS.

Authorisation and Additional Information

This announcement was authorised by the CEO Dr Ralph Highnam.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Communications
kwilliamson@we-worldwide.com
t: +61 3 8866 1200

ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS Systems, Inc., a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

For more information, visit www.volparasolutions.com.